Cidara Therapeutics Inc
$ 220.50
-0.22%
04 Dec - close price
- Market Cap 6,949,005,000 USD
- Current Price $ 220.50
- High / Low $ 220.69 / 219.86
- Stock P/E N/A
- Book Value 14.40
- EPS -11.21
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.29 %
- ROE -0.69 %
- 52 Week High 221.20
- 52 Week Low 15.22
About
Cidara Therapeutics, Inc. is a forward-thinking biotechnology firm headquartered in San Diego, California, focused on advancing long-acting anti-infective therapies to tackle critical unmet medical needs in infectious diseases. Utilizing its proprietary Cloudbreak™ platform, Cidara is at the forefront of developing innovative treatments that aim to improve patient outcomes and increase treatment adherence. The company's diverse pipeline encompasses promising therapeutics targeting both fungal and bacterial infections, strategically positioning it within the dynamic landscape of infectious disease management and underscoring its commitment to enhancing global health.
Analyst Target Price
$221.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-04-21 | 2025-03-07 | 2024-10-31 | 2024-08-13 | 2024-05-15 | 2024-03-27 | 2023-11-02 | 2023-08-03 | 2023-05-11 | 2023-03-23 |
| Reported EPS | -3.1 | -1.65 | -1.66 | -5.38 | -2.45 | -19.99 | -2.28 | -0.04 | -0.09 | -0.14 | 0.03 | -0.19 |
| Estimated EPS | -2.77 | -3.04 | -3.4725 | -3.6725 | -4.25 | -3.22 | -0.2 | -0.1 | -0.16 | -0.13 | -0.04 | -0.17 |
| Surprise | -0.33 | 1.39 | 1.8125 | -1.7075 | 1.8 | -16.77 | -2.08 | 0.06 | 0.07 | -0.01 | 0.07 | -0.02 |
| Surprise Percentage | -11.9134% | 45.7237% | 52.1958% | -46.4942% | 42.3529% | -520.8075% | -1040% | 60% | 43.75% | -7.6923% | 175% | -11.7647% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CDTX
2025-11-02 11:24:59
Cidara Therapeutics, Inc. has secured up to $339 million from BARDA to advance CD388, a non-vaccine preventive for both pandemic and seasonal influenza. CD388 is an investigational drug-Fc conjugate (DFC) designed to offer long-lasting protection against various flu strains without relying on an immune response, making it potentially effective for immunocompromised individuals, those with comorbidities, and the elderly. The funding will support accelerating domestic production of this innovative flu preventive.
2025-10-16 20:49:39
Cidara Therapeutics' CD388 has received Breakthrough Therapy designation from the FDA for preventing influenza A and B in high-risk patients. This designation was supported by positive results from the Phase 2b NAVIGATE trial, which showed significant prevention of seasonal influenza. CD388, developed using Cidara's Cloudbreak platform, is a long-acting antiviral designed for universal flu prevention with a single dose.
2025-10-16 20:49:37
Cidara Therapeutics (NASDAQ: CDTX) has received Breakthrough Therapy designation from the US FDA for its drug CD388 for the prevention of influenza A and B in high-risk adults and adolescents. This designation is supported by positive results from the Phase 2b NAVIGATE trial, which demonstrated significant prevention of seasonal influenza. CD388, developed using Cidara’s Cloudbreak platform, is a long-acting antiviral intended for universal flu prevention with a single dose.
2025-10-16 14:34:45
Morgan Stanley initiated coverage on Cidara Therapeutics (CDTX) with an "overweight" rating. The investment firm highlighted the potential of Cidara's lead candidate, CD388, a single-dose antiviral for influenza prevention. Morgan Stanley set a price target of $190 for CDTX.
2025-10-13 14:42:45
Cidara Therapeutics, Inc. announced it will present late-breaking data on its lead drug-Fc conjugate (DFC) candidate, CD388, at the 10th ESWI Influenza Conference in October 2025. The presentation will focus on the translational efficacy of CD388 in mouse influenza infection models and its application to prevention efficacy in the recently completed Phase 2b NAVIGATE clinical study. CD388, a long-acting antiviral, has received Fast Track Designation from the FDA and is currently in its Phase 3 ANCHOR trial for seasonal influenza prevention.
2025-10-13 12:54:19
This article from Investing.com indicates that there was an application error preventing the display of the full content. While the headline suggests Cidara was scheduled to present Phase 2 data on an influenza drug at ID Week 2025, no further details or the actual article content are available due to this technical issue.
